Digital Health Interventions to Improve Medication Adherence Among Older Adults: A Systematic Review.

Australas J AgeingSep 1, 2026
Clinical ResearchGeriatricsPreventive Medicine / Public HealthOpen access

Kaleab Taye Haile, Wejdan Shahin, Eyob Alemayehu Gebreyohannes et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the impact of digital health interventions (DHIs) on medication adherence in older adults (aged 65 and above). Among 35 studies, nearly half demonstrated improved adherence with DHIs compared to controls. Notably, interventions featuring tailored reminders and multiple functionalities were most effective, highlighting the potential of DHIs in this population.

Key findings

  • Nearly half of the studies (n=17) reported improved medication adherence with DHIs compared to control or baseline.
  • Mobile apps, electronic reminders, and social assistive robots showed the most promise in enhancing adherence.
  • Interventions with multiple functionalities or strategies to support behavior change were most likely to improve adherence.

Why it matters

Improving medication adherence in older adults is crucial for enhancing health outcomes and reducing hospitalizations. Digital health interventions offer innovative solutions to address adherence challenges in this population, potentially leading to better management of chronic conditions.

Source

PubMed · PMID 42469587Free full text on PubMed Central

Published in Australas J Ageing. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.